Application
DOSAGE REGIMEN FOR A CONTROLLED-RELEASE PTH COMPOUND
Applicants
- ASCENDIS PHARMA BONE DISEASES A
Abstract
The present invention provides at least one controlled release PTH compound, or pharmaceutical formulation thereof, for use in the treatment, control, delay or prevention of conditions that can be treated, controlled, delayed or prevented by PTH. 70 of the molar equivalent dose of PTH 1-84 administered every 24 hours, which is required to maintain serum calcium within normal levels over 24 hours in humans. It relates to a pharmaceutical composition administered at a frequency of no more than once every 24 hours at a dose of controlled release PTH compound corresponding to no more than %.
Patent Family Records (38)
Controlled-release PTH compound
Ascendis Pharma Bone Diseases AS SPROGÿE KENNETT, SPROGØE KENNETT, CLEEMANN FELIX, (...more)
2024, US-11918628-B2
Controlled-release PTH compound
Ascendis Pharma Bone Diseases AS SPROGÿE KENNETT, SPROGØE KENNETT, CLEEMANN FELIX, (...more)
2024, US-11890326-B2
DOSAGE REGIMEN FOR A CONTROLLED-RELEASE PTH COMPOUND
ASCENDIS PHARMA BONE DISEASES A HOLTEN ANDERSEN LARS, HOLTEN-ANDERSEN LARS, SPROGE KENNETT, (...more)
2024, KR-20240013849-A
Dosage Regimen for Controlled Release PTH Compounds
아센디스 파마 본 디지즈 에이/에스 КАРПФ, Дэвид Брайан, СПРОГЕЕ, Кеннетт, ХОЛЬТЕН-АНДЕРСЕН, Ларс, (...more)
2024, KR-102627405-B1
DOSAGE REGIMEN FOR CONTROLLED-RELEASE PTH COMPOUND
Ascendis Pharma Bone Diseases AS LARS HOLTEN-ANDERSEN, KENNETT SPROGOE, DAVID BRIAN KARPF
2024, JP-2024041859-A
DOSAGE REGIMEN FOR A CONTROLLED-RELEASE PTH COMPOUND
ASCENDIS PHARMA BONE DISEASES AS HOLTEN ANDERSEN LARS, HOLTEN-ANDERSEN LARS, SPROGOE KENNETT, (...more)
2024, HU-E063235-T2
Dosing regimen for a controlled release pth compound
Ascendis Pharma Bone Diseases AS HOLTEN ANDERSEN LARS, HOLTEN-ANDERSEN LARS, SPROGÿE KENNETT, (...more)
2024, ES-2959995-T3
DOSAGE REGIMEN FOR A CONTROLLED-RELEASE PTH COMPOUND
Ascendis Pharma Bone Diseases AS HOLTEN ANDERSEN LARS, HOLTEN-ANDERSEN LARS, SPROGÿE KENNETT, (...more)
2024, EP-4275677-A3
Dosage regimen for controlled release of PTH compounds
Ascendis Pharma Bone Diseases AS HOLTEN ANDERSEN LARS, HOLTEN-ANDERSEN LARS, SPROGOE KENNETT, (...more)
2024, CN-117838873-A
Dosage regimen for controlled release of PTH compounds
Ascendis Pharma Bone Diseases AS L. Holden-Anderson, SPROGOEE KENNETT, D.B. Kapf
2024, CN-109789189-B
Controlled-Release PTH Compound
Ascendis Pharma Bone Diseases AS SPROGÿE KENNETT, SPROGØE KENNETT, CLEEMANN FELIX, (...more)
2023, US-20230381284-A1
Dosage Regimen for a Controlled-Release PTH Compound
Ascendis Pharma Bone Diseases AS SPROGÿE KENNETT, SPROGØE KENNETT, CLEEMANN FELIX, (...more)
2023, US-20230321198-A1
Dosage Regimen for a Controlled-Release PTH Compound
Ascendis Pharma Bone Diseases AS SPROGÿE KENNETT, SPROGØE KENNETT, CLEEMANN FELIX, (...more)
2023, US-20230248836-A1
Dosage regimen for a controlled-release PTH compound
Ascendis Pharma Bone Diseases AS HOLTEN ANDERSEN LARS, HOLTEN-ANDERSEN LARS, SPROGÿE KENNETT, (...more)
2023, US-11590207-B2
DOSAGE REGIMEN FOR A CONTROLLED-RELEASE PTH COMPOUND
ASCENDIS PHARMA BONE DISEASES AS HOLTEN ANDERSEN LARS, HOLTEN-ANDERSEN LARS, SPROGOE KENNETT, (...more)
2023, SI-3518960-T1
DOSAGE REGIMEN FOR A CONTROLLED-RELEASE PTH COMPOUND
ASCENDIS PHARMA BONE DISEASES AS HOLTEN ANDERSEN LARS, HOLTEN-ANDERSEN LARS, SPROGÿE KENNETT, (...more)
2023, RS-64440-B1
DOSAGE REGIMEN FOR A CONTROLLED-RELEASE PTH COMPOUND
ASCENDIS PHARMA BONE DISEASES AS HOLTEN ANDERSEN LARS, HOLTEN-ANDERSEN LARS, SPROGÿE KENNETT, (...more)
2023, PL-3518960-T3
DOSAGE REGIMEN FOR A CONTROLLED-RELEASE PTH COMPOUND
ASCENDIS PHARMA BONE DISEASES AS HOLTEN ANDERSEN LARS, HOLTEN-ANDERSEN LARS, SPROGÿE KENNETT, (...more)
2023, LT-3518960-T
Dosing Regimens for Controlled-Release PTH Compounds
Ascendis Pharma Bone Diseases AS LARS HOLTEN-ANDERSEN, KENNETT SPROGOE, DAVID BRIAN KARPF
2023, JP-2023017796-A
DOSAGE REGIMEN FOR A CONTROLLED-RELEASE PTH COMPOUND
ASCENDIS PHARMA BONE DISEASES AS
2023, IL-304086-A
DOSAGE REGIMEN FOR A CONTROLLED-RELEASE PTH COMPOUND
ASCENDIS PHARMA BONE DISEASES AS
2023, IL-265591-B2
Dosage regimen for a controlled-release pth compound
ASCENDIS PHARMA BONE DISEASES AS
2023, IL-265591-B1
DOSAGE REGIMEN FOR A CONTROLLED-RELEASE PTH COMPOUND
ASCENDIS PHARMA BONE DISEASES AS HOLTEN ANDERSEN LARS, HOLTEN-ANDERSEN LARS, SPROGÿE KENNETT, (...more)
2023, HR-P20231079-T1
DOSAGE REGIMEN FOR A CONTROLLED-RELEASE PTH COMPOUND
Ascendis Pharma Bone Diseases AS HOLTEN ANDERSEN LARS, HOLTEN-ANDERSEN LARS, SPROGÿE KENNETT, (...more)
2023, EP-4275677-A2
DOSAGE REGIMEN FOR A CONTROLLED-RELEASE PTH COMPOUND
Ascendis Pharma Bone Diseases AS HOLTEN ANDERSEN LARS, HOLTEN-ANDERSEN LARS, SPROGÿE KENNETT, (...more)
2023, EP-3518960-B1
Dosage schedule for a controlled release PTH compound
ASCENDIS PHARMA BONE DISEASES AS HOLTEN ANDERSEN LARS, HOLTEN-ANDERSEN LARS, KARPF DAVID BRIAN, (...more)
2023, DK-3518960-T3
Dosage Regimen for a Controlled-Release PTH Compound
Ascendis Pharma Bone Diseases AS HOLTEN ANDERSEN LARS, HOLTEN-ANDERSEN LARS, SPROGÿE KENNETT, (...more)
2020, US-20200023041-A1
CONTROLLED RELEASE PTH CONNECTION DOSING MODE
Асцендис Фарма Боун Дизизис А/С КАРПФ, Дэвид Брайан, СПРОГЕЕ, Кеннетт, ХОЛЬТЕН-АНДЕРСЕН, Ларс, (...more)
2020, RU-2019112913-A
DOSAGE REGIMEN FOR A CONTROLLED-RELEASE PTH COMPOUND
ASCENDIS PHARMA BONE DISEASES AS HOLTEN ANDERSEN LARS, HOLTEN-ANDERSEN LARS, SPROGÿE KENNETT, (...more)
2019, ZA-201901811-B
DOSAGE REGIMEN FOR A CONTROLLED-RELEASE PTH COMPOUND
ASCENDIS PHARMA BONE DISEASES AS HOLTEN ANDERSEN LARS, HOLTEN-ANDERSEN LARS, SPROGÿE KENNETT, (...more)
2019, SG-11201901576Q-A
DOSAGE REGIMEN FOR A CONTROLLED-RELEASE PTH COMPOUND.
ASCENDIS PHARMA BONE DISEASES AS KENNETT SPROGØE, LARS HOLTEN-ANDERSEN, DAVID BRIAN KARPF
2019, MX-2019003181-A
Dosage regimen for controlled-release PTH compound
ASCENDIS PHARMA BONE DISEASES A HOLTEN ANDERSEN LARS, HOLTEN-ANDERSEN LARS, SPROGÿE KENNETT, (...more)
2019, KR-20190062496-A
DOSAGE REGIMEN FOR A CONTROLLED-RELEASE PTH COMPOUND
Ascendis Pharma Bone Diseases AS HOLTEN ANDERSEN LARS, HOLTEN-ANDERSEN LARS, SPROGÿE KENNETT, (...more)
2019, EP-3518960-A1
The dosage of controlled release PTH compound
Arsendis Drug Bone Disease Co Ltd HOLTEN ANDERSEN LARS, HOLTEN-ANDERSEN LARS, SPROGOE KENNETT, (...more)
2019, CN-109789189-A
dosing regimen for a controlled release pth compound
ASCENDIS PHARMA BONE DISEASES AS DAVID BRIAN KARPF, KENNETT SPROGØE, LARS HOLTEN-ANDERSEN
2019, BR-112019005533-A2
Dosage regimen for a controlled-release PTH compound
Ascendis Pharma Bone Diseases AS HOLTEN ANDERSEN LARS, HOLTEN-ANDERSEN LARS, SPROGÿE KENNETT, (...more)
2019, AU-2017336249-A1
DOSAGE REGIMEN FOR A CONTROLLED-RELEASE PTH COMPOUND
ASCENDIS PHARMA BONE DISEASES AS HOLTEN ANDERSEN LARS, HOLTEN-ANDERSEN LARS, SPROGÿE KENNETT, (...more)
2018, WO-2018060310-A1
DOSAGE REGIMEN FOR A CONTROLLED-RELEASE PTH COMPOUND
Ascendis Pharma Bone Diseases AS HOLTEN ANDERSEN LARS, HOLTEN-ANDERSEN LARS, SPROGOE KENNETT, (...more)
2018, CA-3037442-A1